Truth be told, Echo Therapeutics Inc. (NASDAQ:ECTE) doesn't look like a particularly impressive stock right now. At $2.92 per share, ECTE is just trading right around where it was a few days ago, not to mention a few weeks ago. And, without any real "news" from the company in months, it's tough to think the market's going to be getting excited about the stock anytime soon. When you take a closer look at Echo Therapeutics though, a few subtle-but-compelling clues start to appear.
ECTE is, in simplest terms, a biopharma name that's developed a handful of specialized medicines, delivery devices, and monitoring devices. Its flagship product - if it has one - is the Symphony glucose monitoring systems for diabetes patients, though it's also working on a needle-free drug delivery product as well. For all intents and purposes, Echo Therapeutics Inc. isn't bearing revenue right now; most of its' (and investors') hopes right now rest on the Symphony trial currently underway in Europe. Those results should be unveiled during the current quarter, with a filing for European approval later in Q4.
Top Dividend Stocks To Invest In Right Now: Barrett Business Services Inc.(BBSI)
Barrett Business Services, Inc. provides business management solutions in the United States. The company offers human resource management services in areas comprising payroll processing, employee benefits and administration, human resource management, risk management, and workers? compensation coverage areas. It also provides professional employer organization services, which include employee benefits, health insurance, workers? compensation coverage, workplace safety programs, federal and state employment laws compliance, labor and workplace regulatory requirements, and related administrative services; and payroll administrative services, such as payroll processing, payroll taxes, and human resource consulting services. In addition, the company provides staffing services, including on-demand or short-term staffing assignments, contract staffing, long-term or indefinite-term on-site management, direct placement, and human resource administration services. It serves elect ronics manufacturers; various light-manufacturing industries; forest products and agriculture-based companies; transportation and shipping enterprises; food processing; telecommunications; public utilities; general contractors in various construction-related fields; and professional services firms. Barrett Business Services, Inc. was founded in 1965 and is headquartered in Vancouver, Washington.
Advisors' Opinion:- [By Rich Duprey]
The much smaller Barrett Business Services (NASDAQ: BBSI ) has done even better, soaring 154% over the last 12 months.
While that might suggest the opportunity to invest in them has passed, I believe their biggest gains are still ahead. While tentativeness among employers about whether the economy is really improving is helping employers to hire more temp workers, the coming implementation of Obamacare will fuel it further. Even with the employer mandate portion of the law being pushed out past the midterm elections to 2015 instead of going into effect on January 1, that just means more companies will be hiring more temp workers for a longer period of time to get below the thresholds the health-care law imposes.
Top 5 Dow Dividend Stocks To Invest In Right Now: Re/Max Holdings Inc (RMAX)
Re/Max Holdings, Inc., incorporated on June 25, 2013, is a franchisor of real estate brokerage services. Its business is to recruit and retain agents and sell franchises. The Company operates in two business segments: Real Estate Franchise Services, and Brokerage and Other. The Company operates in the real estate brokerage franchise industry in more than 90 countries, including the United States and Canada. Effective December 31, 2012, the Company acquired certain assets of RE/MAX of Texas. Effective November 30, 2012, the Company sold substantially all of the assets of owned and operated regional franchising operations located in Eastern Australia and New Zealand and entered into regional franchising agreements with new independent owners of these regions.
The Real Estate Franchise Services reportable segment comprises the operations of its owned and independent global franchising operations. The Brokerage and Other reportable segment contains the operations of its 21 owned brokerage offices in the U.S. which represent less than 1% of RE/MAX brokerages in the U.S., the results of operations of a mortgage brokerage company in which the Company owns a non-controlling interest, the elimination of intersegment revenue and other consolidation entities, as well as corporate and professional services expenses.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Re/Max Holdings (RMAX) have surged out of the gate as investors scoop up shares following the real-estate brokers IPO.
ReutersShares of Re/Max priced at $22, above the range of $19-$21 it had been seeking. The Associated Press has the details:
Re/Max Holdings Inc. has raised $220 million in an initial public offering of its common stock.
Re/Max is giving the underwriters a 30-day option to buy up to an additional 1.5 million shares to cover any excess demand.
The company anticipates about $194.2 million in net proceeds, after underwriting discounts and commissions and estimated offering expenses. Re/Max plans to use the proceeds to reacquire regional Re/Max franchise rights in some markets, redeem preferred membership interests and buy back ownership stakes from existing shareholders.
�Re/Max shares have jumped 21% to $26.67 at 10:32 a.m. Investors might want to reconsider jumping in, however. Here’s what I wrote about IPOs�back in 2011 and it still stands today.The IPO game is notoriously dicey for retail investors. That’s because most of the shares sold at the low offering price go to institutions; only about 20% go to individuals, according to Jay Ritter, a finance professor at the University of Florida.
That means most people must settle for buying new shares during their first few days of trading��rom the bigger investors who are selling. This scenario proved disastrous for investors who bought hot Internet companies near the end of the dot-com boom, just before they crashed.
Most IPOs, in fact, fail to pan out for small investors. Excluding the first day of trading, the average IPO underperforms similarly sized companies by 3.4 percentage points a year during its first five years of trading, according to Prof. Ritter’s data.
The IPO has a mixed impact on other real-estate related companies.�Realogy (RLGY) has fallen 0.2% to $43.62, while Vector Group (VGR), wh
- [By Eric Volkman]
Getty Images/Cultura As more than a few finance industry professionals will happily brag, 2013 was a banner year for initial public offerings with 156 new stocks coming to market -- the most since 2007 -- collectively reaping the issuers aggregate proceeds of more than $38 billion. We went over the most recognizable members of this year's rookie class in "The 5 Most Unfortgettable IPOs of 2013." But in a big pool of 156 companies, there are bound to be at least a few struggling fish. Here, then, is a selection of five from the class of 2013 that are getting seriously lapped by their peers. 1. Prosensa (RNA) This Dutch clinical-stage biopharmaceutical firm had a strong debut when it listed on the Nasdaq in late June. The stock's offer price of $13 zoomed to close at over $19 on the first day of trading. But bad news was waiting around the corner; less than three months later, the shares tanked by more than 70 percent after the company announced that the muscular dystrophy treatment (drisapersen) it was developing in partnership with GlaxoSmithKline (GLAXF), did not hit its primary endpoint in late-stage trials. That one-day free fall saw the stock swoon from $24 per share to barely over $7. Since then, shares have slipped even further, and can currently be had for less than $5. 2. Violin Memory (VMEM) As a provider of high-speed data storage solutions, this company should be well in tune with current IT needs. But it fell flat from the beginning -- on its first day of trading the stock closed slightly over $7 a share, after pricing at $9. Worse was to come when the firm reported its first quarterly results as a publicly traded entity. While revenue advanced nearly 40 percent on a year-over-year basis, that couldn't cover the gaping hole of a bottom line loss totaling $34 million (a figure, by the way, significantly higher than the top line number of $28 million). The already-sinking shares continued to dive, bottoming at just over $2.50 per share. The re
Top 5 Dow Dividend Stocks To Invest In Right Now: OncoMed Pharmaceuticals Inc (OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM] Stocks ended a mini-losing streak on Friday, led by upbeat news from Intel (INTC). The Dow Jones industrial average (^DJI) rose 41 points, after sliding more than 200 over the previous two days. The Nasdaq composite (^IXIC) gained 13 and the Standard & Poor's 500 index (^GPSC) added 6 points. Those modest gains did little to trim the loss for the week. The major averages posted their biggest weekly declines in more than two months. Intel is a component of all three big indexes, and it jumped 7 percent after raising its revenue guidance for the current quarter. The company sees stronger business demand for PCs than it previously expected. Intel shares are up 23 percent over the past six months. The Intel news had a ripple effect. Computer maker Hewlett-Packard (HPQ) rose more than 5 percent and Microsoft (MSFT) gained 1½ percent. Part of the increased demand Intel points to is tied to corporate buyers who need to replace their Windows XP machines, because Microsoft has stopped providing technical support for that platform. But Apple (AAPL) lost more than 1 percent. The stock is down since its 7-for-1 stock split took effect on Monday. There were two other big stories that had some legs beyond the companies directly involved. Open Table (OPEN) agreed to be acquired by Priceline (PCLN) for $2.6 billion. Open Table, which provides restaurant reservations, jumped 48 percent. Other online service providers rode the coattails of that deal. Yelp (YELP) gained 14 percent and Groupon (GRPN) gained 4 percent. In the retail arena, Express (EXPR) jumped 21 percent after a private equity firm took a 9.9 percent stake in the teen retailer and indicated it may make a buyout offer. That gave a boost to Aeropostale (ARO) and American Eagle (AEO), which both rose more than 2 percent. Abercrombie & Fitch (ANF) gained 1½. Elsewhere, International Game Technology (IGT) gained 10½ percent on a Reuters report that a bidding war could erupt for
- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
The U.S. Food and Drug Administration on Wednesday imposed a partial clinical hold on a second cancer treatment trial by OncoMed Pharmaceuticals Inc.(OMED) The FDA’s action follows a similar hold last Friday on another treatment targeting cancer stem cells.
Top 5 Dow Dividend Stocks To Invest In Right Now: Templeton Emerging Markets Fund (EMF)
Templeton Emerging Markets Fund (the Fund) is a diversified, closed-end investment company. The Fund seeks long-term capital appreciation by investing at least 80% of its net assets in emerging country equity securities. It makes investments in China, Brazil, South Korea, Turkey, Russia, Thailand, India, Taiwan, Hungary and South Africa. The Fund invests in sectors, such as metals and mining, commercial banks, diversified financial services, semiconductors and semiconductor equipment, wireless telecommunication services, and oil, gas and consumable fuels.
Templeton Asset Management Ltd. (TAML) serves as the Fund�� investment manager. Its administrative manager is Franklin Templeton Services, LLC. The Fund may invest in the Franklin Institutional Fiduciary Trust Money Market Portfolio (the Sweep Money Fund), an open-end investment company managed by Franklin Advisers, Inc. (an affiliate of TAML).
Advisors' Opinion:- [By George Putnam, Editor, New Generation Research, Inc.]
Templeton Emerging Markets Fund (EMF) is also actively managed. Currently, the fund is Asian-centric with about 71% of assets from Asian markets, mostly China and Thailand.
No comments:
Post a Comment